FDA on Tylenol recall 2010: This ain’t over
Tylenol recalls in 2009
There were a few small, specific Tylenol recalls in 2009. First, in September, Tylenol recalled 80-milligram Children’s Tylenol Meltaways packaged in bottles and blisters, 80-milligram Children’s Tylenol SoftChews packaged in blisters, and 160-milligram Jr. Tylenol Meltaways packaged in blisters. That recall was because of confusing dosage instructions.
Then, foreshadowing the Tylenol recall in 2010, in December Tylenol recalled Arthritis Pain Caplet 100 count bottles with the red EZ-Open Cap because users reported a moldy smell, and some experienced nausea and sickness. Well, apparently that nausea-inducing moldy smell was present in more than just the Arthritis Pain Caplet 100 count bottles with the red EZ-Open Cap. Tylenol parent company Johnson & Johnson might end up needing to hit up some money lenders to stay in the over-the-counter drug business.
Tylenol recall 2010
Here we are, day 15 of 2010. Johnson & Johnson division McNeil-PPC has issued recalls on the following:
- junior strength Motrin
- children’s Tylenol grape meltaway tablets
- extra strength Tylenol
- extra strength Tylenol rapid release gelcap
- extra strength Tylenol PM geltab
- Motrin caplets
- extra strength Rolaids fresh mint tablets
- St. Joseph Aspirin chewable orange tablets
Um, is that all? Furthermore, after the Tylenol recall of 2010, who is going to trust any of their products. The reason for the massive Tylenol recall of 2010 is, again, “unusual moldy, musty or mildew-like” odor, says CNN Money. The first instances of this problem were reported in 2008. Now the FDA has issued a warning to McNeil.
FDA response to Tylenol recall of 2010
Besides the warning letter, the FDA has released public statements, saying:
“The company should have acted faster. All companies have a responsibility to ensure high quality, safety and effectiveness of their products and protect consumers.”
The FDA says it will “aggressively investigate and solve the problem.” The warning letter says McNeil has 15 days to report on its efforts to address the current problem and prevent it from reoccurring.